Free Republic 2nd Qtr 2025 Fundraising Target: $81,000 Receipts & Pledges to-date: $79,241
97%  
Woo hoo!! And we're now over 97%!! Thank you all very much!! God bless.

Keyword: solidtumors

Brevity: Headers | « Text »
  • Case report: Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing (80% success with various solid cancer tumors)

    05/27/2023 5:05:49 AM PDT · by ConservativeMind · 3 replies
    Medical Xpress / SEngine Precision Medicine / npj Precision Oncology ^ | May 24, 2023 | Mark Zipkin / Heidi J. Gray et al
    Researchers associated with SEngine Precision Medicine, a precision oncology company that matches patients to medicines based on their own tumor samples, have published a new case report showing a patient's remarkable response to an off-label therapy identified by its PARIS Test. Despite standard-of-care chemotherapy and two surgeries, the patient's low-grade serous ovarian cancer (LGSOC) was progressing and her prognosis was terminal. But by testing a range of therapies in organoids grown from the patient's own tumor sample, SEngine's PARIS Test identified as a top candidate ibrutinib, a BTK inhibitor approved only for certain leukemias and lymphomas and with no prior...
  • Tumor-suppressor Protein Gives Up Its Secrets

    07/16/2013 9:18:43 PM PDT · by neverdem · 5 replies
    Biology News Net ^ | July 9, 2013 | NA
    PTEN is shown in its active (above) and inactive (below) forms. Genetic mutations aren't the only thing that can keep a protein called PTEN from doing its tumor-suppressing job. Johns Hopkins researchers have now discovered that four small chemical tags attached (reversibly) to the protein's tail can have the same effect, and they say their finding may offer a novel path for drug design to keep PTEN working. In a report published on July 9 in the journal eLife, the Johns Hopkins scientists describe how a cluster of four phosphate groups, first found 13 years ago to bind to PTEN's...
  • U.S. Cancer Institute 'Megaproject' to Target Common Cancer-Driving Protein

    07/16/2013 9:32:54 PM PDT · by neverdem · 7 replies
    ScienceInsider ^ | 24 June 2013 | Jocelyn Kaiser
    Enlarge Image Harold Varmus Credit: National Cancer Institute It may be dealing with the worst budget crunch in its history, but that is not stopping the National Cancer Institute (NCI) from doing new things. Today, NCI officials outlined a plan to bring together the agency's contract lab in Frederick, Maryland, and outside researchers to find ways to block a mutated protein that drives growth in one-third of all cancers but was thought impossible to "drug" until now. The RAS project, as NCI is calling it, will not entail huge amounts of money—just $10 million that will be reprogrammed from...
  • Fat Kills Cancer: Turning Stem Cells Taken From Fat Tissue Into Personalized, Cancer-targeted...

    07/07/2007 1:13:04 AM PDT · by neverdem · 24 replies · 856+ views
    Turning Stem Cells Taken From Fat Tissue Into Personalized, Cancer-targeted Therapeutics Researchers in Slovakia have been able to derive mesenchymal stem cells from human adipose, or fat, tissue and engineer them into "suicide genes" that seek out and destroy tumors like tiny homing missiles. This gene therapy approach is a novel way to attack small tumor metastases that evade current detection techniques and treatments, the researchers conclude in the July 1 issue of Cancer Research, a journal of the American Association for Cancer Research. "These fat-derived stem cells could be exploited for personalized cell-based therapeutics," said the study's lead investigator,...
  • Possible cause of prostate cancer found

    10/30/2005 10:46:01 PM PST · by neverdem · 84 replies · 2,555+ views
    Seattle Post-Intelligencer ^ | October 28, 2005
    ASSOCIATED PRESS ANN ARBOR, Mich. -- Scientists at the University of Michigan Medical School are part of a team that has discovered a possible cause of prostate cancer, a finding they say could result in better forms of treatment or possibly a cure. The findings show a recurring pattern of scrambled chromosomes that leads to the merging of specific genes. The activity occurs only in prostate cancer. The Michigan researchers, with researchers at the Harvard Medical School-affiliated Brigham and Women's Hospital in Boston, found the abnormality in the majority of prostate cancer tissue samples they analyzed. The gene fusion was...